Filtered By:
Condition: Headache
Education: Study
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 2552 results found since Jan 2013.
Visual Hallucinations following Coronary Artery Bypass Grafting: A Prospective Study
Conclusions: Transient visual hallucinations occur in a noticeable proportion of patients after on-pump heart surgery. Knowledge of the phenomenon's benignity is important for patients to prevent anxiety and uncertainty and for treating physicians to avoid unnecessary medication and drug-induced delirium.PMID:36295626 | PMC:PMC9610531 | DOI:10.3390/medicina58101466
Source: Medicina (Kaunas) - October 27, 2022 Category: Universities & Medical Training Authors: Marlene Tschernatsch Jasmin El Shazly Marius Butz Sa-Ra Lie Mesut Yeniguen Tobias Braun Georg Bachmann Markus Schoenburg Tibo Gerriets Patrick Schramm Martin Juenemann Source Type: research
Comprehensive evaluation of the mechanism of Gastrodia elata Blume in ameliorating cerebral ischemia –reperfusion injury based on integrating fecal metabonomics and 16S rDNA sequencing
Gastrodia elata Blume was used to treat stroke and headaches caused by “Feng” for thousands of years. The present study has shown a significant effect of G. elata Blume in improving cerebral ischemia–reperfusion injury (CIRI). However, the mechanism of G. elata Blume in improving CIRI by regulating the intestinal flora has not been reported until now. This research aimed to comprehensively evaluate the mechanism of G. elata Blume in CIRI based on fecal metabolomics and 16S rDNA sequencing. The rat model with CIRI was created based on the Zea Longa method. Enzyme-linked immunosorbent assay (ELISA) was used to monitor ...
Source: Frontiers in cellular and infection microbiology - October 27, 2022 Category: Microbiology Source Type: research
U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Short- and long-term outcomes of moyamoya patients post-revascularization
CONCLUSIONS: In this large, single-center surgical series, most of the adult and pediatric patients had direct revascularization, with a 4.2% per-bypass-procedure (6.8% per patient) 30-day major stroke risk and a 0.6% per-patient-year long-term stroke risk. The authors identified various risk factors that are highly correlated with postoperative morbidity (age, mMRI score, and HDR score) and are involved in ongoing work to develop the predictive modeling for future patient selection and treatment.PMID:36272120 | DOI:10.3171/2022.8.JNS22336
Source: Journal of Neurosurgery - October 22, 2022 Category: Neurosurgery Authors: Mario Teo Kumar Abhinav Teresa E Bell-Stephens Venkatesh S Madhugiri Eric S Sussman Tej Deepak Azad Rohaid Ali Rogelio Esparza Michael Zhang Gary K Steinberg Source Type: research
Clinical features of moyamoya disease with Graves' disease: a retrospective study of 394,422 patients with thyroid disease
This study aimed to clarify the characteristics of MMD in patients with Graves' disease. This was a single-center, retrospective study. The prevalence and clinical features of MMD patients among all patients with thyroid disease who visited Ito hospital from January 2005 to December 2019 were evaluated. The relationship between MMD and hyperthyroidism was analyzed in new-onset Graves' disease patients during the same period. Of all 394,422 patients with thyroid disease, 88,180 had Graves' disease, and 40 had MMD with Graves' disease, i.e., the prevalence was 45.36 per 100,000 patients with Graves' disease (0.0454%). The me...
Source: Endocrine Journal - October 5, 2022 Category: Endocrinology Authors: Marino Hiruma Natsuko Watanabe Takako Mitsumatsu Nami Suzuki Miho Fukushita Masako Matsumoto Ai Yoshihara Jaeduk Yoshimura Noh Kiminori Sugino Koichi Ito Source Type: research
